Ann: GDC 0084 progress update, page-2

• Phase II clinical trial on track to commence in fourth quarter of calendar 2017

• Master Services Agreement signed with Chiltern Oncology, a leading international contract research organization, in relation to conduct of the phase ll development program

• Patents granted in five territories, including USA and Australia, since licensing from Genentech

Novogen CEO, Dr James Garner, commented on recent progress, “The GDC-0084 study is on track to commence this year, in line with our prior guidance to the market. Novogen has made excellent progress in designing and setting up a world-class clinical trial for this exciting potential new treatment. The need for new therapeutic options in brain cancer is substantial, and we hope that GDC-0084 will have an important role to play.”